Apolipoprotein B: from editosome to proteasome.
Level 5 - mechanism / opinion, no new human data
Narrative review of basic molecular biology, cellular mechanisms, and animal models
What was done
This narrative review synthesizes research on apolipoprotein B (apoB), detailing historical discoveries regarding its primary structure, mRNA editing (APOBEC-1 editosome), transgenic and knockout animal models, interaction with microsomal triglyceride transfer protein (MTP), and intracellular degradation via the ubiquitin-proteasome pathway.
What was found
The abstract reports no primary experimental data or quantitative metrics. It details foundational mechanistic milestones, including the distinction between apoB-100 and apoB-48, the discovery of mammalian mRNA editing, the requirement of MTP for apoB production, and the finding that constitutive hepatic apoB production is predominantly regulated post-translationally by intracellular proteasomal degradation.
Why it matters
Elucidating the molecular pathways of apoB synthesis, editing, and degradation explains how circulating low-density lipoprotein levels are controlled cellularly and highlights regulatory mechanisms that inform lipid-lowering targets.
Limits
The abstract describes a narrative historical review without a systematic search methodology, meta-analytic data, or clinical human outcome measurements.
Cited by
- supports Apolipoprotein B (apoB) is constitutively synthesized by the liver under tonic stimulation, and hepatic apoB secretion is primarily regulated through degradation rather than changes in its synthesis rate.